BeOne Medicines

Forecast & Rating8 analysts currently cover BeOne Medicines, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is ¥377.47, about 48.8% upside from the current price of ¥253.69. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 61.7% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study BeOne Medicines closely still see room for the stock to rise. Data as of Oct 27, 2026; for reference only and not investment advice.